Antitrust Watchdog Forces Drug Divestitures
The FTC said that without the divestiture, the $2 billion deal would violate U.S. competition laws.
“Just as with generic oral pharmaceutical products, consumers benefit from robust competition in the markets for generic injectable drugs,” said Jeffrey Schmidt, director of the FTC’s Bureau of Competition. “The order requiring the divestiture of the five drugs...
To view the full article, register now.